** Biotech firm Elicio Therapeutics' ELTX.O shares fall 14% to an over 2-month low of $6.71
** ELTX now expects mid-stage study data of its lead experimental vaccine, ELI-002, in Q3 2025 vs. previous expectation of H1 2025
** Co is testing vaccine against certain types of solid tumors that are caused by mutations in the KRAS gene, which are common in pancreatic, colorectal, and non-small cell lung cancers
** ELTX's net loss also widens in 2024 compared with 2023
** As of last close, ELTX has risen 2.5% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.